TherapeuticsMD (NASDAQ:TXMD)‘s stock had its “buy” rating restated by investment analysts at Noble Financial in a research note issued to investors on Friday.
Several other research firms have also weighed in on TXMD. Cantor Fitzgerald restated a “buy” rating and set a $28.00 price target on shares of TherapeuticsMD in a research report on Sunday, January 7th. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 12th. Oppenheimer restated a “buy” rating and set a $10.00 price target on shares of TherapeuticsMD in a research report on Sunday, January 28th. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. Finally, Deutsche Bank set a $9.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $14.50.
TherapeuticsMD (TXMD) opened at $5.47 on Friday. The firm has a market cap of $1,200.00, a PE ratio of -14.39 and a beta of 1.13. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TXMD. MANA Advisors LLC purchased a new stake in TherapeuticsMD during the fourth quarter valued at about $104,000. Paloma Partners Management Co purchased a new stake in TherapeuticsMD during the fourth quarter valued at about $105,000. Edge Wealth Management LLC lifted its holdings in TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock valued at $125,000 after purchasing an additional 20,000 shares during the last quarter. Quantbot Technologies LP purchased a new stake in TherapeuticsMD during the third quarter valued at about $189,000. Finally, Claraphi Advisory Network LLC purchased a new stake in TherapeuticsMD during the fourth quarter valued at about $275,000. 72.81% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3254255/therapeuticsmds-txmd-buy-rating-reiterated-at-noble-financial.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.